Table 4 Summary of outcomes of individual MR gene mutation patients compared to ELN 2022 risk groups.

Summarized are the p-values for statistically significant findings from the log-rank test shown in Supplementary Figs. S1–S9. A # indicates that these mutations are associated with a significantly shorter outcome compared to the ELN 2022 intermediate-risk group, but there is no significant difference compared to the adverse-risk group. A § signifies no significant difference from the intermediate-risk group, but a significantly better outcome compared to the adverse-risk group. All patients in the cohort were retrospectively assigned to ELN 2022 risk groups. For this analysis, patients with MR gene mutation were only considered for the MR gene mutation group if no other class-defining alterations were present. For instance, if a patient was originally only assigned to ELN 2022 adverse risk because of the presence of an MR gene mutation, this patient was allocated to the respective MR gene mutation group. Vice versa, if MR gene mutation bearing patients had co-occurring markers of favorable, intermediate (t(9;11)), or adverse risk, they were allocated to the respective ELN group. Hence, patients in the MR gene mutation group have no other risk-defining markers except for MR gene mutation.

Search